- 營業利益和稅後淨利成長率大於營收成長率, 通常代表公司在成長, 如果是漲很多的股票, 發現沒有這個現象就要留意了
- 營收到某個數字後, 營業利益產生不成比例的增加, 有可能是規模經濟的效應
- 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
- 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
- 如果EPS衰退,要觀察同業是不是有一樣的狀況
- 要留意增資減資和公司債對股本及EPS的影響
加權平均股數 QoQ YoY | EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | 營收 QoQ YoY | 毛利率(%) QoQ YoY | 營業利益 QoQ YoY | 稅後淨利 QoQ YoY | 稅前淨利率(%) QoQ YoY | 稅後淨利率(%) QoQ YoY | 兩季平均(YOY)營收成長率(%) | 兩季平均(YOY)EPS成長率(%) | 兩季平均(YOY)本業EPS成長率(%) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
23Q4 (20) | 22 | 0.0 | 0.0 | 4.19 | 25.07 | 34.73 | 5.05 | 63.43 | 44.29 | 13.39 | 45.54 | 20.74 | 6.44 | 29.84 | 24.08 | 74.20 | 43.49 | 1.78 | 1.29 | 46.59 | 37.23 | 0.93 | 25.68 | 34.78 | 17.18 | -9.53 | 4.25 | 14.47 | -3.6 | 8.96 | 17.02 | 25.04 | 44.77 |
23Q3 (19) | 22 | 0.0 | 0.0 | 3.35 | 25.0 | 39.58 | 3.09 | 26.12 | 28.22 | 9.20 | 57.26 | 15.14 | 4.96 | 4.2 | 16.43 | 51.71 | 5.47 | -0.92 | 0.88 | 35.38 | 25.71 | 0.74 | 23.33 | 39.62 | 18.99 | 26.52 | 16.0 | 15.01 | 19.98 | 20.08 | 5.46 | 4.64 | 0.99 |
23Q2 (18) | 22 | 0.0 | 46.67 | 2.68 | -15.72 | -44.86 | 2.45 | -24.15 | -13.12 | 5.85 | 83.96 | -28.4 | 4.76 | 6.73 | 3.93 | 49.03 | -8.53 | -5.53 | 0.65 | -27.78 | -17.72 | 0.6 | -15.49 | -18.92 | 15.01 | -25.55 | -24.84 | 12.51 | -20.92 | -22.39 | -3.67 | -6.74 | -15.93 |
23Q1 (17) | 22 | 0.0 | 46.67 | 3.18 | 2.25 | -3.93 | 3.23 | -7.71 | 57.56 | 3.18 | -71.33 | -3.93 | 4.46 | -14.07 | 3.24 | 53.60 | -26.47 | 13.32 | 0.9 | -4.26 | 66.67 | 0.71 | 2.9 | 42.0 | 20.16 | 22.33 | 47.15 | 15.82 | 19.13 | 35.68 | 3.88 | 15.91 | 18.76 |
22Q4 (16) | 22 | 0.0 | 46.67 | 3.11 | 29.58 | -30.89 | 3.50 | 45.23 | 11.46 | 11.09 | 38.8 | -32.87 | 5.19 | 21.83 | 5.7 | 72.90 | 39.68 | 32.81 | 0.94 | 34.29 | 10.59 | 0.69 | 30.19 | 1.47 | 16.48 | 0.67 | -3.74 | 13.28 | 6.24 | -4.25 | 7.42 | -10.52 | 15.34 |
22Q3 (15) | 22 | 46.67 | 46.67 | 2.40 | -50.62 | -45.33 | 2.41 | -14.54 | -19.67 | 7.99 | -2.2 | -33.53 | 4.26 | -6.99 | 1.67 | 52.19 | 0.56 | -0.8 | 0.7 | -11.39 | -15.66 | 0.53 | -28.38 | -19.7 | 16.37 | -18.03 | -16.44 | 12.50 | -22.46 | -21.73 | -0.49 | -1.89 | 11.51 |
22Q2 (14) | 15 | 0.0 | 0.0 | 4.86 | 46.83 | 8.0 | 2.82 | 37.56 | -11.32 | 8.17 | 146.83 | 7.08 | 4.58 | 6.02 | 15.08 | 51.90 | 9.73 | -5.15 | 0.79 | 46.3 | -9.2 | 0.74 | 48.0 | 8.82 | 19.97 | 45.77 | -6.94 | 16.12 | 38.25 | -6.44 | -3.00 | 10.19 | 1.43 |
22Q1 (13) | 15 | 0.0 | 0.0 | 3.31 | -26.44 | 5.75 | 2.05 | -34.71 | -4.21 | 3.31 | -79.96 | 5.75 | 4.32 | -12.02 | 26.32 | 47.30 | -13.83 | -8.67 | 0.54 | -36.47 | -10.0 | 0.5 | -26.47 | 6.38 | 13.70 | -19.98 | -21.85 | 11.66 | -15.93 | -16.89 | 2.58 | -11.96 | -15.02 |
21Q4 (12) | 15 | 0.0 | 0.0 | 4.50 | 2.51 | 14.21 | 3.14 | 4.67 | 17.16 | 16.52 | 37.44 | 33.98 | 4.91 | 17.18 | 55.87 | 54.89 | 4.33 | -2.49 | 0.85 | 2.41 | 11.84 | 0.68 | 3.03 | 15.25 | 17.12 | -12.61 | -28.84 | 13.87 | -13.15 | -27.27 | 11.23 | 0.03 | -0.50 |
21Q3 (11) | 15 | 0.0 | 0.0 | 4.39 | -2.44 | 74.9 | 3.00 | -5.66 | 69.49 | 12.02 | 57.54 | 43.1 | 4.19 | 5.28 | 73.86 | 52.61 | -3.86 | -3.11 | 0.83 | -4.6 | 50.91 | 0.66 | -2.94 | 73.68 | 19.59 | -8.71 | -12.19 | 15.97 | -7.31 | -0.31 | 10.83 | 20.67 | 21.47 |
21Q2 (10) | 15 | 0.0 | 0.0 | 4.50 | 43.77 | 49.5 | 3.18 | 48.6 | 55.12 | 7.63 | 143.77 | 29.54 | 3.98 | 16.37 | 65.83 | 54.72 | 5.66 | 2.36 | 0.87 | 45.0 | 50.0 | 0.68 | 44.68 | 51.11 | 21.46 | 22.42 | -11.29 | 17.23 | 22.81 | -10.63 | 12.47 | 11.61 | 14.23 |
21Q1 (9) | 15 | 0.0 | 0.0 | 3.13 | -20.56 | 8.68 | 2.14 | -20.15 | 9.74 | 3.13 | -74.61 | 8.68 | 3.42 | 8.57 | 46.78 | 51.79 | -7.99 | 0.04 | 0.6 | -21.05 | 7.14 | 0.47 | -20.34 | 9.3 | 17.53 | -27.14 | -27.17 | 14.03 | -26.43 | -25.96 | 19.64 | 18.20 | 15.63 |
20Q4 (8) | 15 | 0.0 | 7.14 | 3.94 | 56.97 | 50.38 | 2.68 | 51.41 | 51.41 | 12.33 | 46.79 | -20.19 | 3.15 | 30.71 | 29.63 | 56.29 | 3.66 | 4.9 | 0.76 | 38.18 | 31.03 | 0.59 | 55.26 | 59.46 | 24.06 | 7.84 | 3.0 | 19.07 | 19.04 | 23.19 | 15.57 | 20.18 | 18.88 |
20Q3 (7) | 15 | 0.0 | 7.14 | 2.51 | -16.61 | -33.77 | 1.77 | -13.66 | -26.56 | 8.40 | 42.61 | -34.63 | 2.41 | 0.42 | -8.71 | 54.30 | 1.57 | 0.46 | 0.55 | -5.17 | -20.29 | 0.38 | -15.56 | -28.3 | 22.31 | -7.77 | -14.29 | 16.02 | -16.91 | -21.85 | 1.71 | -6.05 | -4.27 |
20Q2 (6) | 15 | 0.0 | 7.14 | 3.01 | 4.51 | -38.45 | 2.05 | 5.13 | -31.67 | 5.89 | 104.51 | -34.99 | 2.4 | 3.0 | -14.29 | 53.46 | 3.26 | -2.18 | 0.58 | 3.57 | -27.5 | 0.45 | 4.65 | -33.82 | 24.19 | 0.5 | -17.78 | 19.28 | 1.74 | -22.1 | -0.56 | 7.21 | 7.65 |
20Q1 (5) | 15 | 7.14 | 7.14 | 2.88 | 9.92 | -30.94 | 1.95 | 10.17 | -26.14 | 2.88 | -81.36 | -30.94 | 2.33 | -4.12 | -6.8 | 51.77 | -3.52 | -4.97 | 0.56 | -3.45 | -20.0 | 0.43 | 16.22 | -25.86 | 24.07 | 3.04 | -13.67 | 18.95 | 22.42 | -20.45 | - | - | 0.00 |
19Q4 (4) | 14 | 0.0 | 0.0 | 2.62 | -30.87 | 0.0 | 1.77 | -26.56 | 0.0 | 15.45 | 20.23 | 0.0 | 2.43 | -7.95 | 0.0 | 53.66 | -0.72 | 0.0 | 0.58 | -15.94 | 0.0 | 0.37 | -30.19 | 0.0 | 23.36 | -10.26 | 0.0 | 15.48 | -24.49 | 0.0 | - | - | 0.00 |
19Q3 (3) | 14 | 0.0 | 0.0 | 3.79 | -22.49 | 0.0 | 2.41 | -19.67 | 0.0 | 12.85 | 41.83 | 0.0 | 2.64 | -5.71 | 0.0 | 54.05 | -1.1 | 0.0 | 0.69 | -13.75 | 0.0 | 0.53 | -22.06 | 0.0 | 26.03 | -11.52 | 0.0 | 20.50 | -17.17 | 0.0 | - | - | 0.00 |
19Q2 (2) | 14 | 0.0 | 0.0 | 4.89 | 17.27 | 0.0 | 3.00 | 13.64 | 0.0 | 9.06 | 117.27 | 0.0 | 2.8 | 12.0 | 0.0 | 54.65 | 0.31 | 0.0 | 0.8 | 14.29 | 0.0 | 0.68 | 17.24 | 0.0 | 29.42 | 5.52 | 0.0 | 24.75 | 3.9 | 0.0 | - | - | 0.00 |
19Q1 (1) | 14 | 0.0 | 0.0 | 4.17 | 0.0 | 0.0 | 2.64 | 0.0 | 0.0 | 4.17 | 0.0 | 0.0 | 2.5 | 0.0 | 0.0 | 54.48 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.58 | 0.0 | 0.0 | 27.88 | 0.0 | 0.0 | 23.82 | 0.0 | 0.0 | - | - | 0.00 |
年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 備註(年增率變動50%需說明原因) |
---|---|---|---|---|---|---|---|---|
2024/2 | 1.62 | -7.04 | 11.14 | 3.36 | 15.64 | 5.14 | N/A | - |
2024/1 | 1.74 | -2.26 | 20.17 | 1.74 | 20.17 | 6.38 | N/A | - |
2023/12 | 1.78 | -37.53 | 16.7 | 20.74 | 13.04 | 6.53 | 0.4 | - |
2023/11 | 2.85 | 50.37 | 31.6 | 18.96 | 12.71 | 6.41 | 0.41 | - |
2023/10 | 1.9 | 14.03 | 29.57 | 16.11 | 9.91 | 5.32 | 0.5 | - |
2023/9 | 1.66 | -5.68 | 20.59 | 14.21 | 7.73 | 4.96 | 0.56 | - |
2023/8 | 1.76 | 15.15 | 23.32 | 12.55 | 6.23 | 4.87 | 0.57 | - |
2023/7 | 1.53 | -2.65 | 5.47 | 10.79 | 3.88 | 4.79 | 0.58 | - |
2023/6 | 1.57 | -6.43 | -0.9 | 9.25 | 3.62 | 4.76 | 0.44 | - |
2023/5 | 1.68 | 11.82 | 4.92 | 7.68 | 4.6 | 4.77 | 0.44 | - |
2023/4 | 1.5 | -5.32 | 6.14 | 6.0 | 4.51 | 4.55 | 0.46 | - |
2023/3 | 1.59 | 9.05 | 11.21 | 4.49 | 3.97 | 4.49 | 0.39 | - |
2023/2 | 1.46 | 0.51 | 6.55 | 2.91 | 0.4 | 4.43 | 0.4 | - |
2023/1 | 1.45 | -5.09 | -5.1 | 1.45 | -5.1 | 5.14 | 0.34 | - |
2022/12 | 1.53 | -29.55 | -7.3 | 18.35 | 11.42 | 5.16 | 0.3 | - |
2022/11 | 2.17 | 48.06 | 22.33 | 16.82 | 13.5 | 5.01 | 0.31 | - |
2022/10 | 1.46 | 6.12 | 0.2 | 14.66 | 12.3 | 4.27 | 0.36 | - |
2022/9 | 1.38 | -3.54 | -0.02 | 13.19 | 13.82 | 4.26 | 0.38 | - |
2022/8 | 1.43 | -1.51 | 0.89 | 11.81 | 15.69 | 4.47 | 0.37 | - |
2022/7 | 1.45 | -8.53 | 3.96 | 10.38 | 18.08 | 4.64 | 0.35 | - |
2022/6 | 1.59 | -0.94 | 10.96 | 8.93 | 20.75 | 4.61 | 0.27 | - |
2022/5 | 1.6 | 13.12 | 16.11 | 7.34 | 23.1 | 4.45 | 0.28 | - |
2022/4 | 1.42 | -0.8 | 21.58 | 5.74 | 25.2 | 4.21 | 0.3 | - |
2022/3 | 1.43 | 4.47 | 20.18 | 4.32 | 26.43 | 4.32 | 0.22 | - |
2022/2 | 1.37 | -10.48 | 24.09 | 2.89 | 29.77 | 4.54 | 0.2 | - |
2022/1 | 1.53 | -7.28 | 35.31 | 1.53 | 35.31 | 4.95 | 0.19 | - |
2021/12 | 1.65 | -7.03 | 35.69 | 16.47 | 60.06 | 4.88 | 0.1 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有累計虧損,長期來看需謹慎觀察 |
2021/11 | 1.77 | 21.27 | 53.37 | 14.82 | 63.32 | 4.61 | 0.1 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有累計虧損,長期來看需謹慎觀察 |
2021/10 | 1.46 | 5.88 | 87.53 | 13.05 | 64.77 | 4.26 | 0.11 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察 |
2021/9 | 1.38 | -2.65 | 67.03 | 11.59 | 62.29 | 4.19 | 0.1 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察 |
2021/8 | 1.42 | 1.48 | 81.09 | 10.21 | 61.67 | 4.25 | 0.1 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察 |
2021/7 | 1.4 | -2.38 | 74.18 | 8.79 | 58.92 | 4.21 | 0.1 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察 |
2021/6 | 1.43 | 3.65 | 72.55 | 7.4 | 56.34 | 3.98 | 0.1 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察 |
2021/5 | 1.38 | 18.46 | 68.72 | 5.96 | 52.89 | 3.73 | 0.11 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察 |
2021/4 | 1.17 | -1.94 | 55.77 | 4.58 | 48.69 | 3.46 | 0.12 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察 |
2021/3 | 1.19 | 7.87 | 53.06 | 3.42 | 46.42 | 3.42 | 0.07 | 因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚在虧損中,長期來看需謹慎觀察。 |
2021/2 | 1.1 | -2.38 | 40.2 | 2.23 | 43.11 | 3.44 | 0.07 | - |
2021/1 | 1.13 | -7.02 | 46.07 | 1.13 | 46.07 | 3.5 | 0.07 | - |
2020/12 | 1.21 | 5.07 | 35.46 | 10.29 | -0.77 | 3.15 | 0.03 | - |
2020/11 | 1.16 | 48.28 | 58.69 | 9.08 | -4.2 | 2.76 | 0.04 | 因1111單身節與購物節檔期,使直播、交友與保健品收入都有所增加,有可能為短期效應,長期來看還需謹慎觀察。 |
2020/10 | 0.78 | -5.68 | -3.52 | 7.92 | -9.43 | 2.39 | 0.04 | - |
2020/9 | 0.83 | 5.53 | -3.61 | 7.14 | -10.04 | 2.41 | 0.01 | - |
2020/8 | 0.78 | -2.39 | -12.98 | 6.31 | -10.81 | 2.41 | 0.01 | - |
2020/7 | 0.8 | -3.29 | -8.77 | 5.53 | -10.5 | 2.45 | 0.01 | - |
2020/6 | 0.83 | 1.35 | -13.54 | 4.73 | -10.78 | 2.4 | 0.02 | - |
2020/5 | 0.82 | 9.36 | -11.1 | 3.9 | -10.18 | 2.34 | 0.02 | - |
2020/4 | 0.75 | -3.64 | -18.62 | 3.08 | -9.93 | 2.31 | 0.02 | - |
2020/3 | 0.78 | -1.18 | -16.47 | 2.33 | -6.74 | 2.33 | 0.04 | - |
2020/2 | 0.79 | 1.69 | -1.5 | 1.56 | -0.99 | 2.45 | 0.04 | - |
2020/1 | 0.77 | -13.77 | -0.46 | 0.77 | -0.46 | 2.4 | 0.04 | - |
2019/12 | 0.9 | 23.09 | -10.39 | 10.37 | 24.94 | 2.43 | 0.04 | - |
2019/11 | 0.73 | -9.84 | -11.53 | 9.47 | 29.78 | 2.39 | 0.04 | - |
2019/10 | 0.81 | -5.77 | -3.44 | 8.75 | 35.03 | 2.56 | 0.04 | - |
2019/9 | 0.86 | -4.73 | 19.27 | 7.94 | 40.73 | 2.64 | 0.04 | - |
2019/8 | 0.9 | 2.33 | 30.31 | 7.08 | 43.87 | 2.74 | 0.04 | - |
2019/7 | 0.88 | -8.34 | 50.09 | 6.18 | 46.08 | 2.76 | 0.04 | 因「愛情公寓iPair」交友APP新推出之「直播聊天功能」大受好評,使各主播收禮分潤收入屢創新高,故本月營收較去年同期大幅成長 |
2019/6 | 0.96 | 4.21 | 39.46 | 5.3 | 45.43 | 2.8 | 0.04 | - |
2019/5 | 0.92 | 0.11 | 38.46 | 4.34 | 46.82 | 2.77 | 0.04 | - |
2019/4 | 0.92 | -1.11 | 58.69 | 3.42 | 49.25 | 0.0 | N/A | 因「愛情公寓iPair」交友APP新推出之「直播聊天功能」大受好評,使各主播收禮分潤收入屢創新高,故本月營收較去年同期大幅成長 |
2019/3 | 0.93 | 16.53 | 34.17 | 2.5 | 46.05 | 0.0 | N/A | - |
加權平均股數 YoY | EPS YoY | 本業EPS YoY | 營收 YoY | 毛利率(%) YoY | 營業利益 YoY | 稅前淨利 YoY | 稅後淨利 YoY | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 (10) | 22 | 0.0 | 13.37 | 20.89 | 13.82 | 28.8 | 20.62 | 12.37 | 58.52 | 2.97 | 3.72 | 25.68 | 3.66 | 19.61 | 2.98 | 21.14 |
2022 (9) | 22 | 46.67 | 11.06 | -32.56 | 10.73 | -6.7 | 18.35 | 11.21 | 56.83 | 5.97 | 2.96 | -6.03 | 3.06 | -1.92 | 2.46 | -1.6 |
2021 (8) | 15 | 0.0 | 16.40 | 34.65 | 11.50 | 36.09 | 16.5 | 60.35 | 53.63 | -0.94 | 3.15 | 28.57 | 3.12 | 27.87 | 2.5 | 35.14 |
2020 (7) | 15 | 7.14 | 12.18 | -19.6 | 8.45 | -13.95 | 10.29 | -0.77 | 54.14 | -0.15 | 2.45 | -11.55 | 2.44 | -12.23 | 1.85 | -14.75 |
2019 (6) | 14 | 0.0 | 15.15 | 15.65 | 9.82 | 18.74 | 10.37 | 24.94 | 54.22 | 1.78 | 2.77 | 36.45 | 2.78 | 33.01 | 2.17 | 15.43 |
2018 (5) | 14 | 0.0 | 13.10 | 0 | 8.27 | 0 | 8.3 | 70.43 | 53.27 | -5.45 | 2.03 | 0 | 2.09 | 0 | 1.88 | 0 |
2017 (4) | 14 | 7.69 | -0.64 | 0 | -0.14 | 0 | 4.87 | 46.69 | 56.34 | -18.76 | -0.03 | 0 | -0.09 | 0 | -0.09 | 0 |
2016 (3) | 13 | 0.0 | -6.31 | 0 | -3.82 | 0 | 3.32 | 36.63 | 69.35 | -12.9 | -0.84 | 0 | -0.85 | 0 | -0.85 | 0 |
2015 (2) | 13 | 0.0 | -5.68 | 0 | -3.27 | 0 | 2.43 | -7.6 | 79.62 | -4.43 | -0.72 | 0 | -0.71 | 0 | -0.71 | 0 |
2014 (1) | 13 | 8.33 | 1.08 | -83.12 | 0.64 | -81.23 | 2.63 | -14.05 | 83.31 | 0 | 0.17 | -81.52 | 0.17 | -82.47 | 0.14 | -82.5 |